Probiotics, prebiotics, and inflammatory bowel disease.

摘要: Publisher Summary Crohn's disease and ulcerative colitis, collectively known as Inflammatory Bowel Disease [“IBD”], are chronic idiopathic relapsing remitting inflammatory disorders of the gastrointestinal tract. These result in tissue-damaging responses intestine that might much personal suffering impaired quality life. Traditional therapeutic strategies for IBD target only host response. Within tract, resident microbiota is an essential health asset crucially influences homeostasis normal structural functional development mucosal immunity. In susceptible individuals, some components become a liability. Genetically-influenced unrestrained immune activation response to local bacterial signals believed contribute pathogenesis IBD. Probiotics commensal micro-organisms, usually bacteria, which can be harnessed benefits. The term ‘probiotic' traditionally refers live micro-organisms. Prebiotics non-digestible food ingredients, polysaccharides or oligosaccharides, beneficially affect by selectively modulating composition enteric microbiota. Therefore, pharmabiotics also embrace prebiotics, well synbiotics genetically modified bacteria. This chapter presents overview host-microbe interface within gut, rationale, role, range pharmabiotic options